Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal

Del Franco, Annamaria; Iannaccone, Giulia; Meucci, Maria Chiara; Lillo, Rosa; Cappelli, Francesco; Zocchi, Chiara; Pieroni, Maurizio; Graziani, Francesca; Olivotto, Iacopo

doi:10.1007/s10741-023-10370-x

Heart Fail Rev

2023

DOI: 10.1007/s10741-023-10370-x

|View full text |Cite|

Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal

Annamaria Del Franco,

Giulia Iannaccone,

Maria Chiara Meucci

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Anderson–Fabry disease management: role of the cardiologist

Pieroni,

Namdar,

Olivotto

et al. 2024

European Heart Journal

View full text Add to dashboard Cite

Anderson–Fabry disease (AFD) is a lysosomal storage disorder characterized by glycolipid accumulation in cardiac cells, associated with a peculiar form of hypertrophic cardiomyopathy (HCM). Up to 1% of patients with a diagnosis of HCM indeed have AFD. With the availability of targeted therapies for sarcomeric HCM and its genocopies, a timely differential diagnosis is essential. Specifically, the therapeutic landscape for AFD is rapidly evolving and offers increasingly effective, disease-modifying treatment options. However, diagnosing AFD may be difficult, particularly in the non-classic phenotype with prominent or isolated cardiac involvement and no systemic red flags. For many AFD patients, the clinical journey from initial clinical manifestations to diagnosis and appropriate treatment remains challenging, due to late recognition or utter neglect. Consequently, late initiation of treatment results in an exacerbation of cardiac involvement, representing the main cause of morbidity and mortality, irrespective of gender. Optimal management of AFD patients requires a dedicated multidisciplinary team, in which the cardiologist plays a decisive role, ranging from the differential diagnosis to the prevention of complications and the evaluation of timing for disease-specific therapies. The present review aims to redefine the role of cardiologists across the main decision nodes in contemporary AFD clinical care and drug discovery.

show abstract

Anderson–Fabry disease management: role of the cardiologist

Pieroni,

Namdar,

Olivotto

et al. 2024

European Heart Journal

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal

Cited by 1 publication

References 104 publications

Anderson–Fabry disease management: role of the cardiologist

Anderson–Fabry disease management: role of the cardiologist

Contact Info

Product

Resources

About